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Detailed genomic characterisation of tumours reported by consortiums such as The 
Cancer Genome Atlas and the International Cancer Gene Consortium has 
established that extensive inter-tumoural heterogeneity exists between patients 
within tumour sites [1-4]. Radiotherapy fractionation is currently delivered as a “one 
size fits all” approach, with uniform fractionation within each organ site. However, the 
inter-tumoural variation described above indicates that there is potential to 
individualise fractionation within tumour sites to maximise therapeutic gain. 
Realisation of such potential necessitates understanding the molecular biology 
underlying sensitivity to fraction sizeunderpinning the linear-quadratic model. This 
article will discuss our current understanding of molecular mechanisms underpinning 
fraction size sensitivity, and highlight its relevance in the context of immuneoncology. 
 
Cellular proliferation and fraction-size sensitivity 
 
Normal tissue responses to radiotherapy provide us with a clear inverse association 
between proliferative indices and fraction size sensitivity [5]. For example, gastrointestinal 
mucosa and epidermis have relatively high proliferative indices and are 
insensitive to fraction size, whereas late reacting normal tissues, such as kidney and 
spinal cord, have low proliferative indices and are very sensitive to fraction size [6]. 
The hypothesis that the same association extends to tumours has been tested in 
translational studies using diagnostic tissue from the START and CHHiP randomised 
trials of fractionation in breast and prostate cancer respectively [7, 8]. The START 
trials included START- P (pilot), START- A and START- B which collectively 
recruited 5861 women with early breast cancer. In START-P and START-A, a 
regimen of 50 Gy in 25 fractions over 5 weeks was compared with 42.9 Gy, 41·6 Gy 
or 39 Gy in 13 fractions over 5 weeks (maintaining the same overall treatment time). 
In the pragmatic START-B, a regimen of 50 Gy in 25 fractions over 5 weeks was 
compared with 40 Gy in 15 fractions over 3 weeks. For the CHHiP trial, 3216 men 
with localised prostate cancer were randomised 1:1:1 to receive a standard 
fractionation schedule of 74 Gy in 37 fractions or one of two hypofractionated 
schedules: 60 Gy in 20 fractions or 57 Gy in 19 fractions. 
 
In both of the above translational studies proliferation was assessed using 
immunohistochemistry for Ki67. Primary breast cancer resection specimens from 
181 evaluable patients in the START-P and –A trials who had experienced local 
recurrence were evaluated [9]. Using diagnostic biopsies from patients in CHHiP, 
173 cases with recurrence were matched to 173 controls without recurrence [10]. 
Both studies found no association between proliferation and recurrence according to 
fractionation schedule, although in Trans-CHHiP Ki67 did predict recurrence 
independently of established prognostic factors, including Gleason score [10]. 
Although both these studies provide reassurance that modestly hypofractionated 
schedules do not lead to inferior outcomes for breast and prostate tumours with high 
proliferative indices, they do not definitively disprove a link between proliferation and 
fraction sensitivity. Bearing in mind that the difference in fraction sizes is modest in 
both trials, these studies suggest that proliferation index alone is insufficient to 
discriminate between tumour fraction size sensitivities. In CHHiP, the 
hypofractionated schedules had a shorter overall treatment time than standard 
fractionation, leading to a potential confounding effect due to accelerated 
repopulation. Finally, most patients in CHHiP received androgen deprivation therapy 
which exerts an anti-proliferative effect [11], possibly weakening the association with 
fraction size sensitivity [8]. 
 
DNA repair and fraction-size sensitivity 
 
At the molecular level, proliferating versus non-proliferating cells process their 
radiation induced DNA double strand breaks (DSB) differently. G0/G1 cells rely 
heavily on error-prone non-homologous end joining (NHEJ) and alternative NHEJ 
whereas S/G2 cells are able to use high fidelity homologous recombination (HR) 
[12]. Defective NHEJ has been associated with loss of fraction sensitivity and HR 
can mediate resistance to fraction size sensitivity [13, 14]. Pre-clinical studies 
deciphering this mechanism have been previously described in this journal [15]. 
Elucidating the functionality of NHEJ versus HR using diagnostic tumour tissue 
where a genotoxic treatment has not yet been delivered is challenging. Proficiency of 
HR has been successfully evaluated using pre and post chemotherapy evaluation of 
RAD51 foci [16, 17]. Delivery of “test dose” radiotherapy is not currently feasible prior 
to deciding optimal fractionation, although ex-vivo irradiation has been tested [18, 
19]. Next-generation sequencing of DNA repair genes is increasingly used for 
selection of targeted therapy in castration-resistant prostate cancer [20]. There may 
therefore be a future role for targeted sequencing of DNA repair genes to assist 
individualised radiotherapy fractionation. 
 
P53 and fraction-size sensitivity 
 
Our group has recently shown that fraction size sensitivity, measured by split-dose 
recovery in a range of normal and malignant human cells, is dependent on the 
presence of wild-type (WT) p53 [21]. Prostate tumour cells with mutant p53 (PC3) 
showed no difference in survival when irradiated with 4x1Gy daily fractions versus 
4Gy acute dose in contrast to p53 WT cells (LNCaP) [21]. p53 mutation is a relatively 
uncommon event in primary prostate cancer (occurring in 8% of tumours[4]) and is 
consistent with the above pre-clinical observations that prostate tumours on average 
show a high fraction size sensitivity [8, 22]. In contrast, p53 mutation in lung cancer 
is much more common (81% of squamous cell tumours) [1, 2]. Lung tumours tend to 
show much less fraction sensitivity and have a much higher average alpha/beta ratio 
than prostate tumours [23]. A study measuring tumour growth delay in two genetic 
variants of a lung adenocarcinoma mouse model after either a single fraction of 
11.6Gy or two fractions of 7.3Gy, found no statistically significant difference in the 
response of lung tumours deficient in p53 to the single versus two smaller doses in 
contrast to tumours with WT p53 [24]. If pre-clinical observations hold true in human 
tumours, it may be possible to improve radiotherapy response by using 
hypofractionated schedules in p53 WT tumours and standard fractionation to a 
higher total dose in p53 mutant tumours. 
 
Fraction size in the context of the immune response to radiotherapy 
 
In the era of immune-oncology, an improved understanding of how radiation-induced 
cell kill contributes to the immune response and vice versa, including the impact of 
different fractionation schedules, is a research priority. The synergy of radiation with 
immune checkpoint blockade (ICB) is a particular research focus at present [25]; 
however, the immune response according to fractionation is also likely to be 
important when using radiotherapy alone in the curative setting. 
The specific radiotherapy fraction size used appears to be important in achieving the 
so-called abscopal response to radiation plus ICB. Using TSA mouse mammary 
carcinomas and MCA38 mouse colorectal carcinomas in syngeneic 
immunocompetent C57BL/6 mice, synergy with CTLA4 blockade in terms of distant 
control was better using 3x8Gy than a single 20Gy fraction [26]. Fractions of 8Gy 
enabled maximal induction of cytosolic DNA and a subsequent type 1 interferon 
response via cGAS/STING. However, with 20Gy the DNA exonuclease Trex1 was 
induced, which degraded cytosolic DNA, thus precluding downstream production of 
interferon-beta. 
Translation of these mechanistic insights to human cancers offers potential to 
maximise the abscopal response using ICB/radiation combinations for metastatic 
disease, and may also improve control of micro-metastases in locally advanced 
disease. Total dose needs to be considered alongside fraction size, as this also 
impacts synergy with ICB [26]. Further challenges in a clinical context include 
integrating the above with chromosomal instability which varies between tumours 
[27]. Micronuclei arising spontaneously from chromosomal instability can spill 
genomic DNA into the cytoplasm which, via cGAS/STING, activates downstream 
non-canonical NF-KB signalling, rather than type 1 interferons [28]. 
Data assessing the impact of fractionation on other aspects of the innate immune 
response is currently lacking. Low dose irradiation (2Gy) was shown to promote 
infiltration of anti-tumour iNOS expressing macrophages, which were important for 
subsequent T cell recruitment and vascular normalisation; however, higher fraction 
sizes and doses were not evaluated in this study [29]. 
The impact of fractionation on the adaptive immune response is also likely to be 
clinically important. Neo-antigen burden is an important predictive factor for response 
to ICB [30]. It has been proposed that radiotherapy may increase sub-clonal 
neoantigens, potentially causing T cell exhaustion [31], although to our knowledge 
this has not been demonstrated in patients receiving radiotherapy. In a pre-clinical 
context, 5 daily fractions of 2Gy lead to polyclonal expansion of TCR clones in 
irradiated CT26 murine colon tumours, which were predominantly those that existed 
prior to radiotherapy, rather than new clones [32]. Treatment with other fractionation 
schedules of 3x12Gy or a single dose of 7Gy gave similar findings. 
A different study explored the impact of different fractionation schedules on the 
tumour microenvironment using the CT26 and MCA38 tumour models [33]. A single 
ablative dose of radiation (30Gy) transformed the immunosuppressive tumour 
microenvironment resulting in an intense CD8+ T cell tumour infiltrate, and a loss of 
myeloid derived suppressor cells (MDSCs). Much higher rates of tumour control 
occurred than with lower single doses of 15Gy and 20Gy, or 10x3Gy of radiation. 
Interestingly, addition of 10x3Gy after 1x30Gy markedly reduced tumour control 
compared to a single fraction of 30Gy. The CD8 T cell infiltrate reduced at day 35 
from approximately 70% with the single dose alone, to 4-8% with fractionated 
radiation alone or in combination with the single high dose. This finding could have 
important implications for repeated irradiation in the clinic. 
A further study compared 15Gy, 5x3Gy and no irradiation in B16/OVA murine 
melanoma tumours [34]. The authors systematically compared antigen presentation 
in tumour draining lymph nodes, priming and expansion of tumour-reactive T cells, 
tumour immune cell infiltration into the tumour, T cell effector function and tumour 
cell kill between fractionation schedules. All aspects of the immune response 
mentioned above were highest using the single 15Gy schedule. The enhanced 
trafficking and infiltration of tumour-specific T cells with 1x15Gy versus 3x3Gy may 
once again be due to repeated radiation treatments killing activated T cells. 
Finally, using entirely different tumour models of T and B cell lymphoma, Dovedi et al 
showed that the Toll-like receptor (TLR7) agonist, R848 in combination with RT led 
to long-lasting clearance of tumour [35]. Intriguingly, in this model, fractionated 
radiotherapy (5x2Gy) enhanced efficacy of this combination versus a single 10Gy 
fraction. Induction of tumour-specific memory was demonstrated with both 
fractionation schedules. 
The above pre-clinical findings suggest that the immune response to different 
radiotherapy fraction sizes depends on the murine model used and on the ICB, if 
relevant. There has been a rapid expansion in clinical trials using 
radiotherapy/immunotherapy combinations which use a wide range of 
dose/fractionation schedules [25]. Unfortunately, choice of fraction size is not 
underpinned by strong pre-clinical or clinical data and we do not currently have a 
good understanding of the mechanistic basis of differences in immune response 
according to fraction size. Furthermore, research to date has focussed largely on the 
abscopal response; the immunological effects of different fractionation schedules on 
local tumour control in the curative setting also need consideration. Answering such 
questions is a research priority which is important to address using a wide range of 
pre-clinical models and well-designed human studies with translational endpoints. 
Our understanding of the association of the DNA damage response with the immune 
response continues to grow and exciting potential remains for biological tailoring of 
radiotherapy fractionation according to cell cycle checkpoints, DNA repair and the 
immune response. 
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